<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2207200119
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        piqray 200 mg + 50 mg 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALPELISIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C , Protect from light and moisture
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17606.34
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA SCHWEIZ AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PIQRAY is a prescription medicine used in combination with the medicine fulvestrant to treat women who have gone through menopause and men:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), with an abnormal phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) gene, <strong>and </strong>whose disease has progressed on or after endocrine therapy.</p><p>Your healthcare provider will test your cancer for an abnormal &ldquo;PIK3CA&rdquo; gene to make sure that PIQRAY is right for you.</p><p>It is not known if PIQRAY is safe and effective in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Piqray </strong></p><p>If you have had a severe allergic reaction to PIQRAY or are allergic to any of the ingredients in PIQRAY.</p><ul><li>See the end of this Patient Information leaflet for a complete list of the ingredients in PIQRAY.</li><li>See &ldquo;What are the possible side effects of PIQRAY?&rdquo; for signs and symptoms of severe allergic reaction</li></ul><p>&nbsp;</p><p><strong>b. Take special care with Piqray</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tell your healthcare provider about all of your medical conditions</strong><strong> If you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of diabetes or high levels of sugar in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of skin rash, redness of skin, blistering of the lips, eyes or mouth, or skin peeling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. PIQRAY can harm your unborn baby.</p><p>&nbsp;</p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong></p><p>Tell your healthcare provider about all of the medicines you take, including prescription (such as apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John&rsquo;s wort) and over-the-counter medicines, vitamins, and herbal supplements. Taking PIQRAY with other medicines may affect the way Piqray works and may cause side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.</p><p>&nbsp;</p><p><strong>d. Taking Piqray with food and drink.</strong></p><p>You should take Piqray at the same time every day, immediately following food.</p><p><strong>e. Pregnancy and breast-feeding</strong></p><p><strong>Females who are able to become pregnant: </strong></p><p>o&nbsp;&nbsp; Your healthcare provider will check to see if you are pregnant before you start treatment with PIQRAY.</p><p>o&nbsp;&nbsp; You should use effective birth control (contraception) during treatment with PIQRAY and for 1 week after the last dose.</p><p>o&nbsp;&nbsp; Talk to your healthcare provider about birth control methods that may be right for you during this time.</p><p>o&nbsp;&nbsp; If you become pregnant or think you are pregnant, tell your healthcare provider right away.</p><p>&nbsp;</p><p><strong>Males with female partners who are able to become pregnant:</strong></p><p>o&nbsp;&nbsp; <strong>You</strong> should use condoms and effective birth control during treatment with PIQRAY and for 1 week after the last dose. If your female partner becomes pregnant, tell your healthcare provider right away.</p><p>&nbsp;</p><p><strong>Breastfeeding</strong></p><p>o&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if PIQRAY passes into your breast milk. Do not breastfeed during treatment with PIQRAY and for 1 week after the last dose.&nbsp; Talk to your healthcare provider about the best way to feed your baby during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Take PIQRAY exactly as your healthcare provider tells you.</li><li>Take PIQRAY 1 time each day, at about the same time each day.</li><li>Take PIQRAY with food.</li><li>Swallow PIQRAY tablets whole. Do not chew, crush or split the tablets.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take any PIQRAY tablets that are broken, cracked, or that look damaged.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you vomit after taking a dose of PIQRAY, do not take another dose on that day. Take your next dose at your usual time.</p><p><strong>Important</strong>: PIQRAY is used with fulvestrant. You should also read the Patient Information that comes with fulvestrant.</p><p><strong>a. If you take more Piqray than you should</strong></p><p>If you take too much PIQRAY, call your healthcare provider or go to the nearest hospital emergency room right away</p><p><strong>b. If you forget to take Piqray</strong></p><p>If you miss a dose of PIQRAY you may still take it with food up to 9 hours after the time you usually take it. If it has been more than 9 hours after you usually take your dose, skip the dose for that day. The next day, take the dose at your usual time. Do not take 2 doses to make up for a missed dose.</p><p>&nbsp;</p><p><strong>c. If you stop taking Piqray</strong></p><p>Do not change your dose or stop taking PIQRAY unless your healthcare provider tells you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>PIQRAY may cause serious side effects, including: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Severe allergic reactions. </strong>Tell your healthcare provider or get medical help right away if you have trouble breathing, swelling of the face or throat, flushing, rash, fever, or fast heart rate during treatment with PIQRAY.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Severe skin reactions. </strong>Tell your healthcare provider or get medical help right away if you get severe rash or rash that keeps getting worse, reddened skin, flu-like symptoms, blistering of the lips, eyes or mouth, blisters on the skin or skin peeling, and swollen glands, with or without fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>High blood sugar levels (hyperglycemia).</strong> Hyperglycemia is common with PIQRAY and may be severe. Your healthcare provider will check your blood sugar levels and may give you a medicine called metformin before you start treatment with PIQRAY. Your healthcare provider will monitor your blood sugar levels during treatment and may monitor your blood sugar levels more often if you have a history of Type 2 diabetes. Tell your healthcare provider right away if you develop symptoms of hyperglycemia, including:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; more frequent urination than usual or a higher amount of urine than normal</p><ul><li>increased appetite with weight loss</li></ul><ul><li>confusion</li><li>nausea</li><li>vomiting</li><li>fruity odor on breath</li><li>difficulty breathing</li><li>dry or flushed skin</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lung problems (pneumonitis). </strong>Tell your healthcare provider right away if you develop new or worsening symptoms of lung problems, including:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath or trouble breathing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Diarrhea or colitis (inflammation of your intestines). </strong>Diarrhea is common with PIQRAY and maybe severe. Severe diarrhea can lead to the loss of too much body water (dehydration) and kidney injury. Tell your healthcare provider right away if you develop diarrhea, stomach-area (abdominal) pain, or see mucus or blood in your stool during treatment with PIQRAY. Your healthcare provider may tell you to drink more fluids or take medicines to treat diarrhea or colitis.</p><p>Your healthcare provider may tell you to decrease your dose, temporarily stop your treatment, or completely stop your treatment with PIQRAY if you get certain serious side effects.</p><p><strong>The most common side effects of PIQRAY when used with fulvestrant include:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness and weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth sores</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in certain bloodtests</p><p>&nbsp;</p></td></tr></tbody></table><p>Tell your healthcare provider right away if you develop any changes in your vision, eye pain, sensitivity to light, or if your eyes look different.</p><p>&nbsp;</p><p>PIQRAY may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of PIQRAY.</p><p>&nbsp;</p><p>Call your doctor for medical advice about side effects.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30&deg;C. Store in the original package in order to protect from moisture.</p><p>Keep PIQRAY and all medicines out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance of Piqray is alpelisib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 50&nbsp;mg Piqray film‑coated tablet contains 50&nbsp;mg alpelisib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 150&nbsp;mg Piqray film‑coated tablet contains 150&nbsp;mg alpelisib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 200&nbsp;mg Piqray film‑coated tablet contains 200&nbsp;mg alpelisib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Tablet core: Microcrystalline cellulose, mannitol, sodium starch glycolate, hypromellose, magnesium stearate.</p><p>&nbsp;</p><p>Coating material: Hypromellose, iron oxide, titanium dioxide, polyethylene glycol, talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Piqray 50 mg film coated tablets are light pink, round tablets, imprinted with “L7” on one side and “NVR” on the other side.
Piqray 150 mg film coated tablets are pale fred, ovaloid tablets, imprinted with “UL7” on one side and “NVR” on the other side.
Piqray 200 mg film coated tablets are light red, ovaloid tablets, imprinted with “YL7” on one side and “NVR” on the other side.

What pack sizes are available?


Strength	Pack sizes
150 mg	Pack of 28 film coated tablets
200 mg	Pack of 14 film coated tablets
Pack of 28 film coated tablets
200 mg+50 mg	Pack of 14 film coated tablets of 50 mg + 14 film coated tablets of 200 mg
Pack of 28 film coated tablet of 50 mg + 28 film
coated tablets of 200 mg

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved / revised by USFDA in 01/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">عقار بيكراي هو عبارة عن دواء وصفي يُستخدم بمصاحبة عقار فولفيسترانت لعلاج السيدات الذين تجاوزو سن انقطاع الطمث والرجال<strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻣﻤﻦ ﯾﻌﺎﻧﻮن ﻣﻦ ﺳﺮطﺎن اﻟﺜﺪي اﻟﻤﺘﻘﺪم اﻹﯾﺠﺎﺑﻲ ﻟﻤﺴﺘﻘﺒﻞ اﻟﮭﺮﻣﻮن واﻟﺴﻠﺒﻲ ﻟﻤﺴﺘﻘﺒﻞ ﻋﺎﻣﻞ ﻧﻤﻮ اﻟﺒﺸﺮة اﻟﺒﺸﺮي - 2 أو ﺳﺮطﺎن اﻟﺜﺪي اﻟﺬي ﻗﺪ اﻧﺘﺸﺮ إﻟﻰ أﺟﺰاء أﺧﺮى ﻣﻦ اﻟﺠﺴﻢ (اﻟﻨﻘﯿﻠﻲ)، اﻟﻤﺼﺤﻮب ﺑﺎﺿﻄﺮاب ﺟﯿﻦ ﻓﺴﻔﺎﺗﯿﺪﯾﻞ إﯾﻨﻮزﯾﺘﻮل 3 ﻛﯿﻨﺎز اﻟﻮﺣﺪة اﻟﻔﺮﻋﯿﺔ اﻟﺘﱠﺤﻔﯿﺰﯾﺔ أﻟﻔﺎ (PIK3CA)، و ﻣﻤﻦ ﺗﻘﺪﱠم ﻟﺪﯾﮭﻢ اﻟﻤﺮض أﺛﻨﺎء ﺗﻠﻘﻲ ﻋﻼج اﻟﻐﺪد اﻟﺼﻤﺎء أو ﺑﻌﺪه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺳﯿﺨﺘﺒﺮ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﻣﺮض اﻟﺴﺮطﺎن ﻟﺪﯾﻚ ﻟﻠﻜﺸﻒ ﻋﻤﺎ إذا ﻛﺎن ﻟﺪﯾﻚ اﺿﻄﺮاب ﺑﺠﯿﻦ &quot;PIK3CA&quot; أم ﻻ؛ وذﻟﻚ ﻟﻠﺘﺄﻛﺪ ﻣﻦ أنﱠ ﻋﻘﺎر ﺑﯿﻜﺮاي ﻣﻨﺎﺳﺒﺎً ﻟﺤﺎﻟﺘﻚ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻣﻦ ﻏﯿﺮ اﻟﻤﻌﺮوف ﻣﺎ إذا ﻛﺎن ﻋﻘﺎر ﺑﯿﻜﺮاي آﻣﻨﺎً وﻓﻌﺎﻻّ ً ﻋﻨﺪ اﺳﺘﺨﺪاﻣﮫ مع اﻷطﻔﺎل أم ﻻ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال بيكراي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻻ ﺗﺘﻨﺎول ﻋﻘﺎر ﺑﯿﻜﺮاي إذا ﻛﻨﺖ ﻗﺪ ﻋﺎﻧﯿﺖ ﻣﻦ أﺣﺪ ﺗﻔﺎﻋﻼت اﻟﺤﺴﺎﺳﯿﺔ اﻟﺸﺪﯾﺪة ﺗﺠﺎه اﻟﻌﻘﺎر أو ﻛﺎن ﻟﺪﯾﻚ ﺣﺴﺎﺳﯿﺔ ﺗﺠﺎه أي ﻣﻦ ﻣﻜﻮﻧﺎﺗﮫ.</p><p dir="RTL">&bull; اﻧﻈﺮ ﻧﮭﺎﯾﺔ ﻧﺸﺮة ﻣﻌﻠﻮﻣﺎت اﻟﻤﺮﯾﺾ ھﺬه ﻟﻼطﻼع ﻋﻠﻰ اﻟﻘﺎﺋﻤﺔ اﻟﻜﺎﻣﻠﺔ ﻟﻤﻜﻮﻧﺎت ﻋﻘﺎر ﺑﯿﻜﺮاي.</p><p dir="RTL">&bull; اﻧﻈﺮ &quot;ﻣﺎ الأعراض اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤُﺤﺘﻤَﻠﺔ ﻟﻌﻘﺎر ﺑﯿﻜﺮاي؟&quot; ﻟﻼطﻼع ﻋﻠﻰ ﻋﻼﻣﺎت وأﻋﺮاض ﺗﻔﺎﻋﻼت اﻟﺤﺴﺎﺳﯿﺔ اﻟﺸﺪﯾﺪة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال بيكراي</strong></p><p dir="RTL">ﻗﺒﻞ ﺗﻨﺎوﻟﻚ ﻟﻌﻘﺎر ﺑﯿﻜﺮاي، أﺧﺒﺮ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﺑخصوص ﺟﻤﯿﻊ اﻟﺤﺎﻻت اﻟﻄﺒﯿﺔ اﻟﺘﻲ ﺗﻌﺎﻧﻲ ﻣﻨﮭﺎ، وﯾﺸﻤﻞ ذﻟﻚ ﻣﺎ ﯾﻠﻲ:</p><p dir="RTL">&bull; إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ ﻣﺮﺿﻲ ﻣﻦ اﻹﺻﺎﺑﺔ ﺑﻤﺮض اﻟﺴﱡﻜﱠﺮِي أو ارتفاع مستويات السكر في الدم</p><p dir="RTL">&bull; إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ مرَﺿﻲ ﻣﻦ اﻹﺻﺎﺑﺔ ﺑﻄﻔﺢ ﺟﻠﺪي أو اﺣﻤﺮار اﻟﺠﻠﺪ أو ظﮭﻮر ﺑﺜﻮر ﻋﻠﻰ اﻟﺸﻔﺘﯿﻦ أو اﻟﻌﯿﻨﯿﻦ أو اﻟﻔﻢ أو ﺗﻘﺸﱡﺮ اﻟﺠﻠﺪ.</p><p dir="RTL">&bull; إذا ﻛﻨﺖِ ﺣﺎﻣﻼً أو ﺗﺨﻄﻄﯿﻦ ﻟﻠﺤَﻤْﻞ. ﻗﺪ ﯾﻀﺮ ﻋﻘﺎر ﺑﯿﻜﺮاي ﺑﺠﻨﯿﻨﻚِ .</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أخبر مقدم الرعاية الصحية الخاص بك عن جميع الأدوية التي تتناولها (مثل أبالوتاميد، كاربامازيبين، إنزالوتاميد، ميتوتان، فينيتوين، ريفامبين، نبتة سانت جون)، بما في ذلك الأدوية التي تصرف بدون وصفة طبية والفيتامينات والمكملات العشبية. تناول بيكراي مع أدوية أخرى قد يؤثر على طريقة عمل دواء بيكراي وقد يسبب أعراضًا جانبية. احتفظ بقائمة لجميع الأدوية التي تتناولها لإظهارها لمقدم الرعاية الصحية أو الصيدلي الخاص بك عند حصولك على دواء جديد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>د. تناول بيكراي مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تأخذ بيكراي في نفس الوقت كل يوم ، مباشرة بعد الطعام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هـ. </strong><strong>الحمل والرضاعة </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>اﻹﻧﺎث ﻣﻤﻦ ﻟﺪﯾﮭﻦ اﻟﻘﺪرة ﻋﻠﻰ اﻟﺤﻤﻞ: </strong></p><p dir="RTL">o ﺳﯿﻔﺤﺼﻚِ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚِ ؛ ﻟﻤﻌﺮﻓﺔ ﻣﺎ إذا ﻛﻨﺖِ ﺣﺎﻣﻼً أم ﻻ ﻗﺒﻞ ﺑﺪء اﻟﻌﻼج ﺑﻌﻘﺎر ﺑﯿﻜﺮاي.</p><p dir="RTL">o ﻋﻠﯿﻚِ اﺳﺘﺨﺪام وﺳﯿﻠﺔ ﻓﻌﱠﺎﻟﺔ ﻟﻤﻨﻊ اﻟﺤَﻤْﻞ أﺛﻨﺎء اﻟﻌﻼج ﺑﻌﻘﺎر ﺑﯿﻜﺮاي وﻟﻤﺪة أﺳﺒﻮع ﺑﻌﺪ ﺗﻨﺎول اﻟﺠﺮﻋﺔ اﻷﺧﯿﺮة. ﺗﺤﺪﱠﺛﻲ إﻟﻰ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚِ ﺑخصوص طﺮق ﻣﻨﻊ اﻟﺤَﻤْﻞ اﻟﺘﻲ ﻗﺪ ﺗﻨﺎﺳﺒﻚِ ﺧﻼل ھﺬا اﻟﻮﻗﺖ.</p><p dir="RTL">o إذا أﺻﺒﺤﺖِ ﺣﺎﻣﻼً أو اﻋﺘﻘﺪتِ أﻧﻚِ ﺣﺎﻣﻞ، ﻓﺄﺧﺒﺮي ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚِ ﻓﻮرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﯾﺠﺐ ﻋﻠﻰ اﻟﺬﻛﻮر ﻣﻤﻦ ﺗﻜﻮن ﻟﺪى زوﺟﺎﺗﮭﻢ اﻟﻘﺪرة ﻋﻠﻰ اﻟﺤَﻤْﻞ</strong><strong>:</strong><strong> </strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﺳﺘﺨﺪام ﻋﻮازل ذﻛﺮﯾﺔ ووﺳﯿﻠﺔ ﻓﻌﱠﺎﻟﺔ ﻟﻤﻨﻊ اﻟﺤَﻤْﻞ أﺛﻨﺎء اﻟﻌﻼج ﺑﻌﻘﺎر ﺑﯿﻜﺮاي وﻟﻤﺪة أﺳﺒﻮع ﺑﻌﺪ ﺗﻨﺎول اﻟﺠﺮﻋﺔ اﻷﺧﯿﺮة. إذا أﺻﺒﺤﺖ زوﺟﺘﻚ ﺣﺎﻣﻼً ، ﻓﺄﺧﺒﺮ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﻓﻮرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الرضاعة</u></strong></p><p dir="RTL">إذا ﻛﻨﺖِ ﺗﺮُﺿﻌﯿﻦ طﻔﻠﻚِ رﺿﺎﻋﺔ طﺒﯿﻌﯿﺔ أو ﺗﺨﻄﻄﯿﻦ ﻟﺬﻟﻚ. ﻓﻤﻦ ﻏﯿﺮ اﻟﻤﻌﺮوف ﻣﺎ إذا ﻛﺎن ﻋﻘﺎر ﺑﯿﻜﺮاي ﯾﻤﺮ ﻓﻲ حليب اﻷم أم ﻻ. ﻻ ﺗﺮُﺿﻌﻲ طﻔﻠﻚِ رﺿﺎﻋﺔ طﺒﯿﻌﯿﺔ أﺛﻨﺎء اﻟﻌﻼج ﺑﻌﻘﺎر ﺑﯿﻜﺮاي وﻟﻤﺪة أﺳﺒﻮع ﺑﻌﺪ ﺗﻨﺎول اﻟﺠﺮﻋﺔ اﻷﺧﯿﺮة. تحدثي مع مقدم الرعاية الصحية الخاص بك حول أفضل&nbsp; طريقة لإطعام طفلك أثناء العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻨﺎول ﻋﻘﺎر ﺑﯿﻜﺮاي ﻛﻤﺎ ﯾﺨﺒﺮك ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﺑﺎﻟﻀﺒﻂ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻨﺎول ﻋﻘﺎر ﺑﯿﻜﺮاي ﻣﺮة واﺣﺪة ﻛﻞ ﯾﻮم، ﻓﻲ اﻟﻮﻗﺖ ﻧﻔﺴﮫ ﺗﻘﺮﯾﺒﺎً ﻣﻦ ﻛﻞ ﯾﻮم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻨﺎول ﻋﻘﺎر ﺑﯿﻜﺮاي ﻣﻊ اﻟﻄﻌﺎم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﺑﺘﻠﻊ أﻗﺮاص ﻋﻘﺎر ﺑﯿﻜﺮاي ﻛﺎﻣﻠﺔ. ﻻ ﺗﻤﻀﻊ اﻷﻗﺮاص أو ﺗﻄﺤﻨﮭﺎ أو ﺗﻘﺴﻤﮭﺎ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻻ ﺗﺘﻨﺎول أي ﻗﺮص ﻣﻜﺴﻮر أو ﻣﺸﻘﻮق أو ﯾﺒﺪو ﺗﺎﻟﻔﺎً ﻣﻦ أﻗﺮاص ﻋﻘﺎر ﺑﯿﻜﺮاي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﺗﻘﯿﺄت ﺑﻌﺪ ﺗﻨﺎول إﺣﺪى ﺟﺮﻋﺎت ﻋﻘﺎر ﺑﯿﻜﺮاي، ﻓﻼ ﺗﺘﻨﺎول ﺟﺮﻋﺔ أﺧﺮى ﻓﻲ ذﻟﻚ اﻟﯿﻮم. ﺗﻨﺎول اﻟﺠﺮﻋﺔ اﻟﺘﱠﺎﻟﯿﺔ اﻟﺨﺎﺻﺔ ﺑﻚ ﻓﻲ ﻣﻮﻋﺪك اﻟﻤﻌﺘﺎد.</p><p dir="RTL"><strong>هام</strong>: يتم استخدام بيكراي مع دواء فولفيسترانت، يجب عليك أيضًا قراءة معلومات المريض المصاحبة لهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من بيكراي</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&bull; إذا ﺗﻨﺎوﻟﺖ ﻛﻤﯿﺔ أﻛﺜﺮ ﻣﻤﺎ ﯾﺠﺐ ﻣﻦ ﻋﻘﺎر ﺑﯿﻜﺮاي، ﻓﺎﺗﺼﻞ ﺑﻤﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ أو اذھﺐ ﻓورًا إﻟﻰ ﻏﺮﻓﺔ اﻟﻄﻮارئ ﺑﺄﻗﺮب ﻣﺴﺘﺸﻔﻰ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان تناول جرعة من بيكراي</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&bull; إذا نسيت ﺗﻨﺎوُل إﺣﺪى ﺟﺮﻋﺎت ﻋﻘﺎر ﺑﯿﻜﺮاي، ﻓﻼ ﯾﺰال ﺑﺈﻣﻜﺎﻧﻚ ﺗﻨﺎوﻟﮭﺎ ﻣﻊ اﻟﻄﻌﺎم ﺣﺘﻰ ﻣﺮور 9 ﺳﺎﻋﺎت ﺑﻌﺪ وﻗﺖ اﻟﺘﱠﻨﺎوُل اﻟﻤُﻌﺘﺎد. إذا ﺗﺠﺎوزت ﻓﺘﺮة نسيانك اﻟﺠﺮﻋﺔ 9 ﺳﺎﻋﺎت ﺑﻌﺪ وﻗﺖ اﻟﺘﱠﻨﺎوُل اﻟﻤُﻌﺘﺎد، ﻓﺘﺠﺎوز ﺟﺮﻋﺔ ذﻟﻚ اﻟﯿﻮم. ﻓﻲ اﻟﯿﻮم اﻟﺘﱠﺎﻟﻲ، ﺗﻨﺎول اﻟﺠﺮﻋﺔ ﻓﻲ اﻟﻮﻗﺖ اﻟﻤﻌﺘﺎد. ﻻ ﺗﺘﻨﺎول ﺟﺮﻋﺘﯿﻦ ﻟﺘﻌﻮﯾﺾ ﺟﺮﻋﺔ نسيتها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج. التوقف عن تناول بيكراي</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&bull; ﻻ ﺗﻐﯿﺮ ﺟﺮﻋﺘﻚ أو ﺗﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎوُل ﻋﻘﺎر ﺑﯿﻜﺮاي ﻣﺎ ﻟﻢ ﯾﺨﺒﺮك ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﺑﺬﻟﻚ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تفاعلات حساسية شديدة.</strong> أخبر مقدم الرعاية الصحية الخاص بك أو احصل على المساعدة الطبية فوراً إذا اصبت بصعوبة بالتنفس أو تورم في الوجه أو الحلق أو احمرار الجلد أو طفح جلدي أو حمى أو تسارع معدل ضربات القلب أثناء العلاج بعقار بيكراي.</p><p dir="RTL"><strong>تفاعلات جلدية شديدة:</strong> أخبر مقدم الرعاية الصحية الخاص بك أو احصل على مساعدة طبية على الفور إذا تعرضت لطفح جلدي شديد أو طفح جلدي يزداد سوءًا أو احمرار الجلد أو أعراض شبيهة بالإنفلونزا أو تقرحات في الشفاه أو العينين أو الفم أو بثور على الجلد أو تقشر الجلد و تورم في الغدد، مع أو بدون حمى</p><p dir="RTL"><strong>فرط السكر بالدم.</strong> فرط السكر بالدم هي حالة شائعة الحدوث مع العلاج بعقار بيكراي ويمكن أن تكون شديدة. سيفحص مقدم الرعاية الصحية الخاص بك مستويات السكر لديك في الدم وقد يعطيك دواء يسمى ميتفورمين قبل بدء العلاج بعقار بيكراي. سيراقب مقدم الرعاية الصحية الخاص بك مستويات السكر في الدم خلال فترة العلاج وقد يراقب مستويات السكر لديك في الدم في كثير من الأحيان إذا كان لديك تاريخ مرضي من الإصابة بمرض السكري من النوع &quot;2&quot;. اخبر مقدم الرعاية الصحية الخاص بك فوراً إذا أصبت بأعراض فرط السكر بالم, والتي تشمل مايلي:</p><ul><li dir="RTL">العطش الشديد</li><li dir="RTL">جفاف الفم</li><li dir="RTL">التبول بمعدل أكثر تكرارا من المعتاد أو بكمية بول أكثر من الطبيعية</li><li dir="RTL">زيادة الشهية مع فقدان الوزن</li><li dir="RTL">ارتباك</li><li dir="RTL">غثيان</li><li dir="RTL">قيء</li><li dir="RTL">رائحة فاكهة في النفس</li><li dir="RTL">صعوبة في التنفس</li><li dir="RTL">جفاف او احمرار في الجلد</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﻣﺸﺎﻛﻞ ﻓﻲ اﻟﺮﺋﺔ (اﻻﻟﺘﮭﺎب اﻟﺮﺋﻮي)</strong>. أﺧﺒﺮ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﻓﻮرًا إذا أُﺻِﺒﺖ ﺑﺄﻋﺮاض ﺟﺪﯾﺪة أو ﻣﺘﻔﺎﻗﻤﺔ ﻟﻤﺸﺎﻛﻞ اﻟﺮﺋﺔ، وﯾﺸﻤﻞ ذﻟﻚ ﻣﺎ ﯾﻠﻲ:</p><ul><li dir="RTL">ضيق أو صعوبة في التنفس.</li><li dir="RTL">سُعال</li><li dir="RTL">ألم في الصدر</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إﺳﮭﺎل أو إلتهاب القولون (إلتهاب الأمعاء).</strong> اﻹﺳﮭﺎل ھﻮ ﺣﺎﻟﺔ ﺷﺎﺋﻌﺔ اﻟﺤﺪوث ﻣﻊ اﻟﻌﻼج ﺑﻌﻘﺎر ﺑﯿﻜﺮاي وﯾﻤﻜﻦ أن ﯾﻜﻮن ﺷﺪﯾﺪاً. ﻗﺪ ﯾﺆدي اﻹﺳﮭﺎل اﻟﺸﺪﯾﺪ إﻟﻰ ﻓﻘﺪان ﻛﻤﯿﺔ ﻛﺒﯿﺮة ﻟﻠﻐﺎﯾﺔ ﻣﻦ اﻟﻤﺎء اﻟﻤﻮﺟﻮد ﻓﻲ اﻟﺠﺴﻢ (ﺟﻔﺎف) وإصابة ﻓﻲ اﻟﻜﻠﻰ. ﺄﺧﺒِﺮ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﻓﻮرًا إذا أصبت ﺑﺈﺳﮭﺎل أو ألم في منطقة المعدة (البطن)، أو اذا رأيت مخاط أو دم في البراز أﺛﻨﺎء اﻟﻌﻼج ﺑﻌﻘﺎر ﺑﯿﻜﺮاي، ﻗﺪ ﯾﺨﺒﺮك ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﺑﺘﻨﺎول ﻛﻤﯿﺎت أﻛﺒﺮ ﻣﻦ اﻟﺴﻮاﺋﻞ أو ﺗﻨﺎول أدوﯾﺔ ﻟﻌﻼج اﻹﺳﮭﺎل أو إلتهاب القولون.</p><p dir="RTL">ﻗﺪ ﯾﺨﺒﺮك ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﺑﺨﻔﺾ ﺟﺮﻋﺘﻚ أو إﯾﻘﺎف ﻋﻼﺟﻚ ﻣﺆﻗﺘﺎً أو إﯾﻘﺎف ﻋﻼﺟﻚ ﺗﻤﺎﻣًﺎ ﺑﻌﻘﺎر ﺑﯿﻜﺮاي إذا أﺻﺒﺖ ﺑﺒﻌﺾ الأعراض اﻟﺠﺎﻧﺒﯿﺔ اﻟﺨﻄﯿﺮة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض اﻟﺠﺎﻧﺒﯿﺔ اﻷﻛﺜﺮ ﺷﯿﻮﻋًﺎ ﻟﻌﻘﺎر ﺑﯿﻜﺮاي ﻋﻨﺪ اﺳﺘﺨﺪاﻣﮫ ﻣﻊ ﻋﻘﺎر ﻓﻮﻟﻔﯿﺴﺘﺮاﻧﺖ ﺗﺸﻤﻞ ﻣﺎ ﯾﻠﻲ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻧﺨﻔﺎض في اﻟﺸﮭﯿﺔ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻓﻘﺪان اﻟﻮزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﻐﺜﯿﺎن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻘﺮﺣﺎت اﻟﻔﻢ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﺴﺎﻗﻂ اﻟﺸﻌﺮ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب وضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻐﯿﱡﺮات ﻓﻲ ﺑﻌﺾ ﻧﺘﺎﺋﺞ اﺧﺘﺒﺎرات اﻟﺪﱠم</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا لاحظت أي تغييرات في الرؤية لديك، أو ألم في العين، أو حساسية للضوء، أو إذا كانت عيناك تبدو مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻘﺪ ﯾﺆﺛﺮُ ﻋﻘﺎر ﺑﯿﻜﺮاي ﻋﻠﻰ اﻟﺨﺼﻮﺑﺔ ﻟﺪى اﻟﺬﻛﻮر واﻹﻧﺎث ﻣﻤﻦ ﻟﺪﯾﮭﻦ اﻟﻘﺪرة ﻋﻠﻰ اﻟﺤَﻤْﻞ. ﺗﺤﺪﱠث إﻟﻰ ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ إذا ﻛﺎن ھﺬا اﻷﻣﺮ ﻣﺼﺪر ﻗﻠﻖ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻚ. ﻣﺎ ﺳﺒﻖ ﻻ ﯾﻤﺜﻞ ﺟﻤﯿﻊ الأعراض اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺤﺘﻤﻠﺔ ﻟﻌﻘﺎر ﺑﯿﻜﺮاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اﺗﺼﻞ ﺑﻄﺒﯿﺒﻚ ﻟﻠﺤﺼﻮل ﻋﻠﻰ الاستشارة اﻟﻄﺒﯿﺔ ﺑخصوص الأعراض اﻟﺠﺎﻧﺒﯿﺔ.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻻ ﯾُﺨﺰﱠن ﻓﻲ درﺟﺔ ﺣﺮارة ﺗﺘﻌﺪى 30 درﺟﺔ ﻣﺌﻮﯾﺔ، وﺗﺘﻢ ﺣﻤﺎﯾﺘﮫ ﻣﻦ اﻟﺮطﻮﺑﺔ.</p><p dir="RTL">ﯾﺤُﻔﻆ ﻋﻘﺎر ﺑﯿﻜﺮاي وﺟﻤﯿﻊ اﻷدوﯾﺔ ﺑﻌﯿﺪاً ﻋﻦ ﻣﺘﻨﺎول اﻷطﻔﺎل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">اﻟﻤﻜﻮّن اﻟﻔﻌﺎل: أﻟﺒﯿﻠﯿﺴﯿﺐ</p><p dir="RTL">&nbsp;</p><p dir="RTL">- كل قرص يحتوي على 50 مجم من أقراص بيكراي يحتوي على 50 مجم من الألبيليسيب.</p><p dir="RTL">- يحتوي كل قرص 150 مجم من أقراص بيكراي على 150 مل من الألبيليسيب.</p><p dir="RTL">- يحتوي كل قرص 200 مجم من أقراص بيكراي على 200 مجم من الألبيليسيب.</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">جوهر القرص : ﺳﻠﯿﻠﻮز دﻗﯿﻖ اﻟﺘﱠﺒﻠﻮر ، مانيتول ، جليكولات نشا الصوديوم ، هيدروميلوز ، ستيرات المغنيسيوم</p><p dir="RTL">مواد الطلاء: ھﯿﺒﺮوﻣﯿﻠﻮز ، أكسيد الحديد ، ثاني أكسيد التيتانيوم ، ﺑﻮﻟﻲ إﯾﺜﯿﻠﯿﻦ اﻟﺠﻼﯾﻜﻮل ،تالك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong>بيكراي 50 مجم أقراص مغلفة بلون وردي فاتح وأقراص دائرية مطبوع عليها حرف &quot;L7&quot; من جانب و &quot;NVR&quot; على الجانب الآخر.</p><p dir="RTL">بيكراي150 أقراص مغلفة بلون أحمر فاتح وأقراص بيضاوية مطبوع عليها &quot;UL7&quot; على جانب و &quot;NVR&quot; على الجانب الآخر.</p><p dir="RTL">بيكراي 200 مجم أقراص مغلفة &nbsp;بلون أحمر فاتح و أقراص بيضاوية فاتحة ، مطبوع عليها علامة &quot;YL7&quot; على جانب و &quot;NVR&quot; على الجانب الآخر.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما أحجام العبوات المتوفرة </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>التركيزات </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>احجام العبوات </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">150 مجم</p></td><td style="vertical-align:top"><p dir="RTL">ﻋﺑوة ﻣن 28 ﻗرصً ﻣﻐﻠﱠف</p><p dir="RTL">&nbsp;ﻋﺑوة ﻣن 56 ﻗرصً ﻣﻐﻠﱠف</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">200 مجم</p></td><td style="vertical-align:top"><p dir="RTL">ﻋﺑوة ﻣن 14 ﻗرصً ﻣﻐﻠﱠف</p><p dir="RTL">ﻋﺑوة ﻣن 28 ﻗرصً ﻣﻐﻠﱠف</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">200 مجم + 50 مجم</p></td><td style="vertical-align:top"><p dir="RTL">ﻋﺑوة ﻣن 14 ق ﻗرصً ﻣﻐﻠﱠف 50 ﻣﺟم + 14 ﻗرصً ﻣﻐﻠﱠف 200 ﻣﺟم&nbsp;</p><p dir="RTL">ﻋﺑوة ﻣن 28 ﻗرصً ﻣﻐﻠﱠف 50 ﻣﺟم + 28&nbsp; ﻗرصً ﻣﻐﻠﱠف 200 ﻣﺟم</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ﻗﺪ ﻻ ﯾﺘﻢ ﺗﺴﻮﯾﻖ ﺟﻤﯿﻊ أﺣﺠﺎم اﻟﻌﺒﻮات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	تم اعتماد هذه النَّشرة من قبل هيئة الغذاء والدواء الأمريكية في:   01/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Piqray 50 mg film coated tablets
Piqray 150 mg film coated tablets
Piqray 200 mg film coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Piqray 50 mg film coated tablets

Each film coated tablet contains 50 mg of alpelisib.

Piqray 150 mg film coated tablets

Each film coated tablet contains 150 mg of alpelisib.

Piqray 200 mg film coated tablets

Each film coated tablet contains 200 mg of alpelisib.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.

Piqray 50 mg film coated tablets

Light pink, unscored, round, curved film coated tablet with bevelled edges, imprinted with “L7” on one side and “NVR” on the other side.

Piqray 150 mg film coated tablets

Pale red, unscored, ovaloid, curved film coated tablet with bevelled edges, imprinted with “UL7” on one side and “NVR” on the other side.

Piqray 200 mg film coated tablets

Light red, unscored, ovaloid, curved film coated tablet with bevelled edges, imprinted with “YL7” on one side and “NVR” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Select patients for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with PIQRAY, based on the presence of one or more PIK3CA mutations in tumor tissue or plasma specimens. If no mutation is detected in a plasma specimen, test tumor tissue.</p><p><u>Posology</u></p><p>The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food.</p><p>Continue treatment until disease progression or unacceptable toxicity occurs.</p><p>Patients should take their dose of PIQRAY at approximately the same time each day.</p><p>Swallow PIQRAY tablets whole (tablets should not be chewed, crushed or split prior to swallowing). No tablet should be ingested if it is broken, cracked, or otherwise not intact.</p><p>If a dose of PIQRAY is missed, it can be taken with food within 9 hours after the time it is usually taken. After more than 9 hours, skip the dose for that day. The next day, take PIQRAY at the usual time.</p><p>If the patient vomits after taking the dose, advise the patient not to take an additional dose on that day, and to resume the dosing schedule the next day at the usual time.</p><p>When given with PIQRAY, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29, and once monthly thereafter. Refer to the Full Prescribing Information for fulvestrant.</p><p>&nbsp;</p><p><em><u>Dose modifications</u></em></p><p>The recommended dose modifications for adverse reactions (ARs) are listed in Table 1.</p><p><strong>Table 1: PIQRAY Dose Reduction Guidelines for Adverse Reactions<sup>1</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>PIQRAY dose level</strong></p></td><td style="vertical-align:top"><p><strong>dose and schedule</strong></p></td><td style="vertical-align:top"><p><strong>Number and strength of tablets</strong></p></td></tr><tr><td style="vertical-align:top"><p>Starting dose</p></td><td style="vertical-align:top"><p>300 mg once daily</p></td><td style="vertical-align:top"><p>Two 150 mg tablets</p></td></tr><tr><td style="vertical-align:top"><p>First-dose reduction</p></td><td style="vertical-align:top"><p>250 mg once daily</p></td><td style="vertical-align:top"><p>One 200 mg tablet and one 50 mg tablet</p></td></tr><tr><td style="vertical-align:top"><p>Second-dose reduction</p></td><td style="vertical-align:top"><p>200 mg once daily<sup>2</sup></p></td><td style="vertical-align:top"><p>One 200 mg tablet</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>Only one dose reduction is permitted for pancreatitis.</p><p><sup>2</sup>If further dose reduction below 200 mg once daily is required, discontinue PIQRAY.</p></td></tr></tbody></table><p>Tables 2, 3, 4, and 5 summarize recommendations for dose interruption, reduction, or discontinuation of PIQRAY<strong> </strong>in the management of specific adverse reactions.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Cutaneous Adverse Reactions</u></p><p>If a severe cutaneous adverse reaction (SCAR) is confirmed, permanently discontinue PIQRAY. Do not reintroduce PIQRAY in patients who have experienced previous SCAR during PIQRAY treatment (see Special warnings and precautions for use).</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Table 2: Dose Modification and Management for Rash and Severe Cutaneous Adverse Reactions (SCARs)</strong></p><p><em>(see Special warnings and precautions for use)</em></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:99%"><thead><tr><td style="vertical-align:top"><p><strong>Grade<sup>1,2</sup></strong></p></td></tr></thead></table></td></tr></tbody></table><p><strong>Recommendation<sup>3</sup> </strong></p><p>Grade 1</p><p>(&lt; 10% body surface area (BSA) with active skin toxicity)</p><p>No PIQRAY dose adjustment required.</p><p>Initiate topical corticosteroid treatment.</p><p>Consider adding oral antihistamine to manage symptoms.</p><p>If active rash is not improved within 28 days of appropriate treatment, add a low dose systemic corticosteroid.</p><p>If the etiology is SCAR, permanently discontinue PIQRAY.</p><p>Grade 2</p><p>(10-30% BSA with active skin toxicity)</p><p>No PIQRAY dose adjustment required.</p><p>Initiate or intensify topical corticosteroid and oral antihistamine treatment.</p><p>Consider low dose systemic corticosteroid treatment.</p><p>If rash improves to Grade &le; 1 within 10 days, systemic corticosteroid may be discontinued.</p><p>If the etiology is SCAR, permanently discontinue PIQRAY.</p><p>Grade 3 (e.g., severe rash not responsive to medical management)</p><p>(&gt; 30% BSA with active skin toxicity)</p><p>Interrupt PIQRAY.</p><p>Initiate or intensify topical/systemic corticosteroid and oral antihistamine treatment.</p><p>If the etiology is SCAR, permanently discontinue PIQRAY.</p><p>If the etiology is not a SCAR, interrupt dose until improvement to Grade &le; 1, then resume PIQRAY at next lower dose level.</p><p>Grade 4 (e.g., severe bullous, blistering or exfoliating skin conditions)</p><p>(any % BSA associated with extensive superinfection, with IV antibiotics indicated: life-threatening consequences)</p><p>Permanently discontinue PIQRAY.</p><p><sup>1</sup>Grading according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0</p><p><sup>2</sup>For all grades of rash, consider consultation with a dermatologist.<em> </em></p><p><sup>3</sup>Antihistamines administered prior to rash onset may decrease incidence and severity of rash based on the SOLAR-1 trial.</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><br /><strong><u>Hyperglycemia</u></strong></p><p>Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose.</p><p>&nbsp;</p><p>&nbsp;</p><p>Consider premedication with metformin prior to the initiation of PIQRAY in combination with fulvestrant based on patient risk factors for hyperglycemia, gastrointestinal tolerability, and clinical situation [see Warnings and Precautions (4.4) and Undesirable Effects (4.8)].&nbsp;</p><p><strong>&nbsp;</strong></p><p>After initiating treatment with PIQRAY, monitor fasting glucose (FPG or fasting blood glucose) at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated. Monitor HbA1c every 3 months and as clinically indicated. In patients with risk factors for hyperglycemia, monitor fasting glucose more closely and as clinically indicated [see Warnings and Precautions].</p><p><strong>Table 3: Dose Modification and Management for Hyperglycemia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:top"><p><strong>Fasting plasma glucose (FPG)/Fasting blood glucose values<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Recommendation</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Dose modifications and management should only be based on fasting glucose values (FPG or fasting blood glucose).</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 1</p><p>Fasting glucose &gt; ULN-160 mg/dL or &gt; ULN-8.9 mmol/L</p></td><td style="vertical-align:top"><p>No PIQRAY dose adjustment required.</p><p>Initiate or intensify anti-diabetic treatment<sup>2</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2</p><p>Fasting glucose &gt; 160-250 mg/dL or &gt; 8.9-13.9 mmol/L</p></td><td style="vertical-align:top"><p>No PIQRAY dose adjustment required.</p><p>Initiate or further intensify anti-diabetic treatment<sup>2</sup>.</p><p>If fasting glucose does not decrease to &le; 160 mg/dL or 8.9 mmol/L within 21 days under</p><p>Appropriate anti-diabetic treatment<sup>2,3</sup>, reduce PIQRAY dose by 1 dose level and follow fasting glucose value specific recommendations</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p><p>&gt; 250-500 mg/dL<br />or &gt; 13.9-27.8 mmol/L</p></td><td style="vertical-align:top"><p>Interrupt PIQRAY.</p><p>Initiate or intensify oral anti- hyperglycemic treatment<sup>2</sup> and consider additional anti- hyperglycemic medications<sup>3</sup> for 1-2 days until hyperglycemia improves, as clinically indicated.</p><p>Administer intravenous hydration and consider appropriate treatment (e.g., intervention for electrolyte/ketoacidosis/hyperosmolar disturbances).</p><p>If fasting glucose decreases to &le; 160 mg/dL or 8.9 mmol/L within 3 to 5 days under appropriate anti- hyperglycemic treatment, resume PIQRAY at 1 lower dose level.</p><p>If fasting glucose does not decrease to &le; 160 mg/dL or 8.9 mmol/L within 3 to 5 days under appropriate anti- hyperglycemic treatment<sup>2,3</sup>, consultation with a physician with expertise in the treatment of hyperglycemia is recommended.</p><p>If fasting glucose does not decrease to &le; 160 mg/dL or 8.9 mmol/L within 21 days following appropriate anti- hyperglycemic treatment<sup>2</sup>, permanently discontinue PIQRAY treatment.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p><p>&gt; 500 mg/dL<br />or &ge; 27.8 mmol/L</p></td><td style="vertical-align:top"><p>Interrupt PIQRAY.</p><p>Initiate or intensify appropriate anti- hyperglycemic treatment<sup>2,3</sup> (administer intravenous hydration and consider appropriate treatment (e.g., intervention for electrolyte/ketoacidosis/hyperosmolar disturbances)), re-check fasting glucose within 24 hours and as clinically indicated.</p><p>If fasting glucose decreases to &le; 500 mg/dL or 27.8 mmol/L, follow fasting glucose value specific recommendations for Grade 3.</p><p>If fasting glucose is confirmed at &gt; 500 mg/dL or 27.8 mmol/L, permanently discontinue PIQRAY treatment.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abbreviation: ULN, upper limit of normal.</p><p>&sup1;FPG/Fasting Blood Glucose/Grade levels reflect hyperglycemia grading according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.</p><p>&sup2;Initiate applicable anti- hyperglycemic medications, including metformin, SGLT2 inhibitors or insulin sensitizers (such as thiazolidinediones or dipeptidyl peptidase-4inhibitors), and review respective prescribing information for dosing and dose titration recommendations, including local hyperglycemic treatment guidelines. Metformin was recommended in the SOLAR-1 trial with the following guidance: Initiate metformin 500 mg once daily. Based on tolerability, metformin dose may be increased to 500 mg twice daily, followed by 500 mg with breakfast, and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed [see Special warnings and precautions for use (4.4)].</p><p>&sup3;As recommended in the SOLAR-1 trial, insulin may be used for 1-2 days until hyperglycemia resolves. However, this may not be necessary in the majority of PIQRAY-induced hyperglycemia, given the short half-life of PIQRAY and the expectation of glucose levels normalizing after interruption of PIQRAY.</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Diarrhea or Colitis</u></strong></p><p><strong>Table 4: Dose Modification and Management for Diarrhea or Colitis</strong></p><p>(see Special warnings and precautions for use)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Grade<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 1</p></td><td style="vertical-align:top"><p>No PIQRAY dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2</p></td><td style="vertical-align:top"><p>Interrupt PIQRAY dose until improvement to Grade &le; 1, then resume PIQRAY at the same dose level.</p><p>For recurrent Grade &ge; 2, interrupt PIQRAY dose until improvement to Grade &le; 1, then resume PIQRAY at the next lower dose level.</p><p>Initiate or intensify appropriate medical therapy and monitor as clinically indicated<sup>2</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>Interrupt PIQRAY dose until improvement to Grade &le; 1, then resume PIQRAY at the next lower dose level.</p><p>Initiate or intensify appropriate medical therapy and monitor as clinically indicated<sup>2</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue PIQRAY.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup>Grading according to CTCAE Version 5.0.</p><p><sup>2</sup>For Grade 2 and 3 colitis consider additional treatment, such as enteric-acting and/or systemic steroids.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Other Toxicities</strong></p><p><strong>Table 5: Dose Modification and Management for Other Toxicities (Excluding Hyperglycemia, Rash</strong><strong> </strong><strong>and Severe Cutaneous Adverse Reactions, and Diarrhea or Colitis)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:top"><p><strong>Grade</strong><sup>1</sup></p></td><td style="vertical-align:top"><p><strong>Recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 1 or 2</p></td><td style="vertical-align:top"><p>No PIQRAY dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated<sup>2,3</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>Interrupt PIQRAY dose until recovery to Grade &le; 1, then resume PIQRAY at the next lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>Permanently discontinue PIQRAY.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup>Grading according to CTCAE Version 5.0</p><p><sup>2</sup>For Grade 2 and 3 pancreatitis, interrupt PIQRAY dose until recovery to Grade &lt; 2 and resume at next lower dose level. Only one dose reduction is permitted. If toxicity reoccurs, permanently discontinue PIQRAY treatment.</p><p><sup>3</sup>For Grade 2 total bilirubin elevation, interrupt PIQRAY dose until recovery to Grade &le; 1 and resume at the same dose if resolved in &le; 14 days or resume at the next lower dose level if resolved in &gt; 14 days.</p></td></tr></tbody></table><p>Refer to the Full Prescribing Information of fulvestrant for dose modification guidelines in the event of toxicity and for other relevant safety information.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p>&nbsp;</p><p><strong><em>Paediatric population</em></strong></p><p>The safety and efficacy of PIQRAY in pediatric patients have not been established.</p><p><strong><em>Elderly </em></strong></p><p>Of 284 patients who received PIQRAY in the SOLAR-1 trial, 117 patients were &ge; 65 years of age and 34 patients were &ge; 75 years of age. In patients treated with PIQRAY plus fulvestrant, there was a higher incidence of Grade 3-4 hyperglycemia in patients &ge; 65 years of age (44%) compared to patients &lt; 65 years of age (32%). No overall differences in effectiveness of PIQRAY were observed between patients &ge; 65 years of age compared to younger patients. There are an insufficient number of patients &ge; 75 years of age to assess whether there are differences in safety or effectiveness. However, in the SOLAR-1 trial, an increase in the hyperglycemia adverse reactions (74% vs 66%) and Grade 3-4 (56% vs 36%) hyperglycemia were observed in patients &ge; 75 years of age compared to patients &lt; 75 years of age, respectively (see Special warnings and precautions for use)</p><p><strong><em>Renal Impairment</em></strong></p><p>The effect of severe renal impairment (CLcr &lt; 30 mL/min) on alpelisib pharmacokinetics is unknown [see&nbsp;Pharmacodynamic properties (5.1)].</p><p>No dose adjustment is recommended for patients with mild to moderate renal impairment (CLcr 30 to &lt; 90 mL/min).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components (see Special warnings and precautions for use)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>Severe Hypersensitivity</strong></p><p>Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia.</p><p>The incidence of Grade 3 and 4 hypersensitivity reactions was 0.7% (<em>see Undesirable effects 4.8</em><strong>)</strong></p><p>Angioedema has been reported in the postmarketing setting in patients treated with PIQRAY [see Undesirable effects (4.8)].</p><p>Advise patients of the signs and symptoms of severe hypersensitivity reactions. Permanently discontinue PIQRAY in the event of severe hypersensitivity.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Severe Cutaneous </strong><strong>Adverse</strong><strong> Reactions</strong><strong> </strong></p><p>Severe cutaneous Adverse reactions(SCARs), including Stevens-Johnson Syndrome (SJS),Erythema Multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in patients treated with PIQRAY.</p><p>In the SOLAR-1 study, SJS and EM were reported in 0.4% and 1.1% of patients, respectively (see Undesirable effects 4.8). Drug reaction with eosinophilia and systemic symptoms (DRESS) was reported in patients treated with PIQRAY in the postmarketing setting (see Undesirable effects 4.8).</p><p>If signs or symptoms of SCARs occur, interrupt PIQRAY until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended.</p><p>If a SCAR is confirmed, permanently discontinue PIQRAY. Do not reintroduce PIQRAY in patients who have experienced previous severe cutaneous reactions during PIQRAY treatment.</p><p>If a SCAR is not confirmed, PIQRAY may require dose modifications, topical corticosteroids, or oral antihistamine treatment as described in Table 2 <em>[see Posology and method of administration (4.2)].</em></p><p>Advise patients of the signs and symptoms of of SCARs (e.g., a prodrome of fever, flu-like symptoms, mucosal lesions or progressive skin rash or lymphadenopathy).</p><p><strong>Hyperglycemia</strong></p><p>Severe hyperglycemia, in some cases associated with hyperglycemic hyperosmolar non-ketotic syndrome</p><p>(HHNKS) or ketoacidosis has occurred in patients treated with PIQRAY. Fatal cases of ketoacidosis have occurred in the post marketing setting.</p><p>&nbsp;Hyperglycemia was reported in 65% of patients treated with PIQRAY. Grade 3 (FPG &gt; 250-500 mg/dL) and Grade 4 (FPG &gt; 500 mg/dL) hyperglycemia was reported in 33% and 3.9% of patients, respectively. Ketoacidosis was reported in 0.7% of patients (n = 2) treated with PIQRAY.</p><p>Among the patients who experienced Grade &ge; 2 (FPG 160-250 mg/dL) hyperglycemia, the median time to first occurrence of hyperglycemia was 15 days (range: 5 to 517 days).</p><p>In the 187 patients with hyperglycemia, 87% (163/187) were&nbsp;managed with anti-diabetic medication, and 76% (142/187) reported use of metformin as single agent or in combination with other anti-diabetic medication [i.e.,&nbsp;insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sulfonylureas]. In patients with Grade &ge; 2 hyperglycemia with at least 1 grade improvement (n = 153), median time to improvement from the first event was 8 days (range: 2 to 65 days).</p><p>In all patients with elevated FPG who continued fulvestrant treatment after discontinuing PIQRAY (n = 54), 96% (n = 52) of patients had FPG levels that returned to baseline.</p><p>Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. After initiating treatment with PIQRAY, monitor&nbsp; fasting glucose(FPG or fasting blood glucose)at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated. Monitor HbA1c every 3 months and as clinically indicated.</p><p>Monitor fasting glucose more frequently for the first few weeks during treatment with PIQRAY in patients with risk factors for hyperglycemia such as obesity (BMI &ge; 30), elevated FPG, HbA1c at the upper limit of normal or above, use of concomitant systemic corticosteroids, or age &ge; 75 (see Special Populations)</p><p>If a patient experiences hyperglycemia after initiating treatment with PIQRAY, monitor fasting glucoseas clinically indicated, and at least twice weekly until&nbsp; fastingglucose decreases to normal levels. During treatment with anti-hyperglycemic medication, continue monitoring fastingglucose at least once a week for 8 weeks, followed by once every 2 weeks and as clinically indicated. Consider consultation with a healthcare practitioner with expertise in the treatment of hyperglycemia and counsel patients on lifestyle changes.</p><p>The safety of PIQRAY in patients with Type 1 and uncontrolled Type 2 diabetes has not been established as these patients were excluded from the SOLAR-1 trial. Patients with a medical history of Type 2 diabetes were included. Patients with a history of diabetes mellitus may require intensified hyperglycemic treatment. Closely monitor patients with diabetes.</p><p>Consider premedication with metformin prior to the initiation of PIQRAY in combination with fulvestrant based on patient risk factors for hyperglycemia, gastrointestinal tolerability, and clinical situation. In the METALLICA study, use of metformin starting 7 days prior to the initiation of PIQRAY appeared to decrease the incidence and severity of hyperglycemia events, but increased the incidence and severity of nausea, vomiting, and diarrhea adverse reactions [see Undesirable Effects (4.8)].</p><p>Based on the severity of the hyperglycemia, PIQRAY may require dose interruption, reduction, or discontinuation as described in Table 3 <em>[see Posology and method of administration (4.2)]. </em></p><p>Advise patients of the signs and symptoms of hyperglycemia (e.g., excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss).</p><p>&nbsp;</p><p><strong>Pneumonitis</strong></p><p>Severe pneumonitis, including acute interstitial pneumonitis and interstitial lung disease, can occur in patients treated with PIQRAY.</p><p>Pneumonitis was reported in 1.8% of patients treated with PIQRAY.</p><p>In patients who have new or worsening respiratory symptoms or are suspected to have developed pneumonitis, interrupt PIQRAY immediately and evaluate the patient for pneumonitis. Consider a diagnosis of non-infectious pneumonitis in patients presenting with non-specific respiratory signs and symptoms such as hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams and in whom infectious, neoplastic, and other causes have been excluded by means of appropriate investigations.</p><p>Permanently discontinue PIQRAY in all patients with confirmed pneumonitis.</p><p>Advise patients to immediately report new or worsening respiratory symptoms.</p><p>&nbsp;</p><p><strong>Diarrhea or Colitis</strong></p><p>Severe diarrhea, resulting in dehydration and in some cases in acute kidney injury, can occurr in patients treated with PIQRAY. Most patients (58%) experienced diarrhea during treatment with PIQRAY. Grade 3 diarrhea occurred in 7% (n&nbsp;=&nbsp;19) of patients. Among patients with Grade 2 or 3 diarrhea (n = 71), the median time to onset was 46 days (range: 1 to 442 days).</p><p>In clinical trials, 63% of patients who experienced diarrhea required antidiarrheal medications (e.g., loperamide) to manage symptoms. Dose reductions of PIQRAY were required in 6% of patients and 2.8% of patients permanently discontinued PIQRAY due to diarrhea.</p><p>Colitis has been reported in the post-marketing setting in patients treated with PIQRAY <em>[see Undesirable effects (4.8)]</em></p><p>Monitor patients for diarrhea and additional symptoms of colitis, such as abdominal pain and mucus or blood in stool. Based on the severity of the diarrhea or colitis, PIQRAY may require dose interruption, reduction, or discontinuation as described in Table 4 [see Posology and method of administration (4.2)]</p><p>Advise patients to start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider if diarrhea occurs while taking PIQRAY.</p><p>Patients with colitis, may require additional treatment, such as enteric-acting and/or systemic steroids, may be required.</p><p>&nbsp;</p><p><strong>Embryo-Fetal Toxicity</strong></p><p>Based on findings in animals and its mechanism of action, PIQRAY can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, oral administration of alpelisib to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes including embryo-fetal mortality (post-implantation loss), reduced fetal weights, and increased incidences of fetal malformations at maternal exposures based on area under the curve (AUC) that were &ge; 0.8 times the exposure in humans at the recommended dose of 300 mg/day. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with PIQRAY and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use condoms and effective contraception during treatment with PIQRAY and for 1 week after the last dose (see Use in Special Populations and Preclinical safety data)</p><p>Refer to the Full Prescribing Information of fulvestrant for pregnancy and contraception information.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><em><u>CYP3A4 Inducers </u></em></p><p>Once-daily administration of 600 mg rifampin (a strong CYP3A4 inducer) for 7 days followed by co-administration with a single 300 mg oral dose of alpelisib on day 8, decreased alpelisib Cmax by 38% and AUC by 57% in healthy adults (N=25). Co-administration of rifampin 600 mg once daily for 15 days with alpelisib 300 mg once daily starting from day 8 to day 15 decreased the steady-state alpelisib Cmax by 59% and AUC by 74%. Co-administration of alpelisib with strong CYP3A4 inducers (e.g. apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John&rsquo;s wort) decreases alpelisib concentration [see Drug Interaction Studies], which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug, with no or minimal potential to induce CYP3A4.</p><p><em><u>Breast Cancer Resistance Protein Inhibitors</u></em></p><p>Coadministration of PIQRAY with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, when PIQRAY is used in combination with BCRP inhibitors, closely monitor for increased adverse reactions.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p><u>Risk Summary</u></p><p>PIQRAY is used in combination with fulvestrant. Refer to the Full Prescribing Information of fulvestrant for pregnancy information.</p><p>Based on animal data and mechanism of action, PIQRAY can cause fetal harm when administered to a pregnant woman (see Pharmacological properties)There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, oral administration of alpelisib to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes including embryo-fetal mortality (post-implantation loss), reduced fetal weights, and increased incidences of fetal malformations at maternal exposures &ge; 0.8 times the exposure in humans based on AUC at the recommended dose of 300 mg/day <em>(see Data). </em>Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. However, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies in the U.S. general population.</p><p><u>Data</u></p><p><em>Animal Data</em></p><p>In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of alpelisib up to 30 mg/kg/day during the period of organogenesis.</p><p>In rats, oral administration of alpelisib resulted in maternal toxicity (body weight loss, low food consumption) and no viable fetuses (post-implantation loss) at 30 mg/kg/day (approximately 3 times the exposure in humans at the recommended dose of 300 mg/day based on AUC). At a dose of 10 mg/kg/day (approximately 0.8 times the exposure in humans at the recommended dose of 300 mg/day based on AUC), toxicities included reduced fetal weight and increased incidences of skeletal malformations (bent scapula and thickened or bent long bones) and fetal variations (enlarged brain ventricle, decreased bone ossification).</p><p>In a pilot embryo-fetal development study in rabbits, a dose of 30 mg/kg/day resulted in no viable fetuses (post-implantation loss). Doses &ge; 15 mg/kg/day resulted in increased embryo-fetal deaths, reduced fetal weights, and malformations, mostly related to the tail and head. At 15 mg/kg/day in rabbits, the maternal exposure was approximately 5 times the exposure achieved at the recommended human dose of 300 mg/day based on AUC.</p><p><strong><u>Breast‑feeding</u></strong></p><p>PIQRAY is used in combination with fulvestrant. Refer to the Full Prescribing Information of fulvestrant for lactation information.</p><p>There is no data on the presence of alpelisib in human milk, its effects on milk production, or the breastfed child. Because of the potential for serious adverse reactions in the breastfed child, advise lactating women to not breastfeed during treatment with PIQRAY and for 1 week after the last dose.&nbsp;</p><p><strong><u>Fertility</u></strong></p><p>PIQRAY is used in combination with fulvestrant. Refer to the Full Prescribing Information of fulvestrant for contraception and infertility information.</p><p><u>Pregnancy Testing</u></p><p>Verify the pregnancy status in females of reproductive potential prior to initiating PIQRAY.</p><p><u>Contraception</u></p><p><em>Females</em></p><p>PIQRAY can cause fetal harm when administered to a pregnant woman <em>[see Use in Specific Populations ]</em>. Advise females of reproductive potential to use effective contraception during treatment with PIQRAY and for 1 week after the last dose.</p><p><em>Males</em></p><p>Advise male patients with female partners of reproductive potential to use condoms and effective contraception during treatment with PIQRAY and for 1 week<em> </em>after the last dose.<em> </em></p><p><u>Infertility</u></p><p>Based on findings from animal studies, PIQRAY may impair fertility in males and females of reproductive potential. (See Preclinical safety data)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>The safety of PIQRAY was evaluated in a randomized, double-blind, placebo-controlled trial (SOLAR-1) in 571 patients with HR-positive, HER2-negative, advanced or metastatic breast cancer enrolled into two cohorts, with or without a PIK3CA mutation<em>. (see Clinical Studies).</em></p><p>Patients received either PIQRAY 300 mg plus fulvestrant (n = 284) or placebo plus fulvestrant (n = 287). Fulvestrant 500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28‑day cycle during treatment phase.</p><p>Two patients (0.7%) died while on treatment with PIQRAY plus fulvestrant due to causes other than the underlying malignancy. Causes of death included one cardio-respiratory arrest and one second primary malignancy. Neither was suspected to be related to study treatment.</p><p>Serious adverse reactions occurred in 35% of patients receiving PIQRAY plus fulvestrant. Serious adverse reactions in &gt; 2% of patients receiving PIQRAY plus fulvestrant included hyperglycemia (10%), rash (3.5%), diarrhea (2.8%), acute kidney injury (2.5%), abdominal pain (2.1%), and anemia (2.1%).</p><p>Osteonecrosis of the jaw (ONJ) was reported in 4.2% of patients (12/284) in the PIQRAY plus fulvestrant arm compared to 1.4% of patients (4/287) in the placebo arm. All patients experiencing ONJ had prior or concomitant bisphosphonates or RANK-ligand inhibitor administration.</p><p>Among patients receiving PIQRAY plus fulvestrant, 4.6% permanently discontinued both PIQRAY and fulvestrant and 21% permanently discontinued PIQRAY alone, due to adverse reactions. The most frequent adverse reactions leading to treatment discontinuation of PIQRAY in &gt; 2% patients receiving PIQRAY plus fulvestrant were hyperglycemia (6%), rash (4.2%), diarrhea (2.8%), and fatigue (2.5%).</p><p>Dose reductions due to adverse reactions occurred in 55% of patients receiving PIQRAY plus fulvestrant. The most frequent adverse reactions leading to dose reduction in &gt; 2% patients receiving PIQRAY plus fulvestrant were hyperglycemia (29%), rash (9%), diarrhea (6%), stomatitis (3.5%) and mucosal inflammation (2.1%).</p><p>The most common adverse reactions including laboratory abnormalities (all grades, incidence &ge; 20%) were glucose increased, creatinine increased, diarrhea, rash, lymphocyte count decreased, GGT increased, nausea, ALT increased, fatigue, hemoglobin decreased, lipase increased, decreased appetite, stomatitis, vomiting, weight decreased, calcium decreased, glucose decreased, aPTT prolonged, and alopecia.</p><p>Adverse reactions and laboratory abnormalities are listed in Table 6 and Table 7, respectively.</p><p>&nbsp;</p><p><strong>Table 6: Adverse Reactions Occurring in &ge; 10% and &ge; 2% Higher than Placebo Arm in SOLAR-1 (All&nbsp;Grades)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:726px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PIQRAY plus fulvestrant<br />N = 284</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo plus fulvestrant<br />N = 287</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3-4</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3-4</strong></p><p><strong>%</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Diarrhea</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>7<sup>*</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.3<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Nausea</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>2.5<sup>*</sup></p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0.3<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Stomatitis<sup>1</sup></p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2.5<sup>*</sup></p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Vomiting</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>0.7<sup>*</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.3<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Abdominal pain<sup>2</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1.4<sup>*</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Dyspepsia</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Fatigue<sup>3</sup></p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>5<sup>*</sup></p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Mucosal inflammation</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>2.1<sup>*</sup></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Edema peripheral</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0.3<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Pyrexia</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>0.3<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Mucosal dryness<sup>4</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.4<sup>*</sup></p></td><td style="vertical-align:top"><p>4.2</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Urinary tract infection<sup>5</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.7<sup>*</sup></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Weight decreased</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>3.9<sup>*</sup></p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Decreased appetite</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>0.7<sup>*</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.3<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Dysgeusia<sup>6</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.4<sup>*</sup></p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Headache</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.7<sup>*</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Rash<sup>7</sup></p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>20<sup>*</sup></p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0.3<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Alopecia</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Pruritus</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.7<sup>*</sup></p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;Dry skin<sup>8</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.4<sup>*</sup></p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Grading according to CTCAE Version 4.03</p><p><sup>1 </sup>Stomatitis: including stomatitis, aphthous ulcer and mouth ulceration</p><p><sup>2</sup> Abdominal pain: abdominal pain, abdominal pain upper, abdominal pain lower</p><p><sup>3</sup> Fatigue: including fatigue, asthenia</p><p><sup>4</sup> Mucosal dryness: including dry mouth, mucosal dryness, vulvovaginal dryness</p><p><sup>5</sup> Urinary tract infection: including UTI and single case of urosepsis&nbsp;</p><p><sup>6</sup> Dysgeusia: including dysgeusia, ageusia, hypogeusia</p><p><sup>7</sup> Rash: including rash, rash maculo-papular, rash macular, rash generalized, rash papular, rash pruritic</p><p><sup>8</sup> Dry skin: including dry skin, skin fissures, xerosis, xeroderma</p><p><sup>* </sup>No Grade 4 adverse reactions were reported.</p></td></tr></tbody></table><p>&nbsp;</p><p>Among the patients with Grade 2 or 3 rash, the median time to first onset of Grade 2 or 3 rash was 12 days. A subgroup of 86 patients received premedication, including anti-histamines, prior to onset of rash. In these patients, rash&nbsp;was reported less frequently than in the overall population, for all&nbsp;grades&nbsp;rash&nbsp;(27% vs 54%), Grade 3 rash (12% vs 20%) and rash leading to permanent discontinuation of PIQRAY (3.5% vs 4.2%).&nbsp;Of the 153 patients who experienced rash, 141 had resolution of the rash.</p><p><strong>Table 7: Laboratory Abnormalities Occurring in &ge; 10% of Patients in SOLAR-1</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:726px"><thead><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>PIQRAY plus fulvestrant<br />N = 284</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo plus fulvestrant<br />N = 287</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Laboratory abnormality</strong></p></td><td style="vertical-align:top"><p><strong>All Grades<br />%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3-4<br />%</strong></p></td><td style="vertical-align:top"><p><strong>All Grades<br />%</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3-4<br />%</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Hematological parameters</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lymphocyte count decreased</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>4.5<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>4.2<sup>*</sup></p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Activated partial thromboplastin time (aPTT) prolonged</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0.7<sup>*</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.3<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Platelet count decreased</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Biochemical parameters</strong></p></td></tr><tr><td style="vertical-align:top"><p>Glucose increased<sup>1</sup></p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine increased</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>2.8<sup>*</sup></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0.7<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gamma glutamyl transferase (GGT) increased</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase (ALT) increased</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2.4<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Calcium (corrected) decreased</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Glucose decreased</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Potassium decreased</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>0.7<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Albumin decreased</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Magnesium decreased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.4<sup>*</sup></p></td><td style="vertical-align:top"><p>4.2</p></td><td style="vertical-align:top"><p>0<sup>*</sup></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1</sup>Glucose increase is an expected laboratory abnormality of PI3K inhibition.</p><p><sup>*</sup>No Grade 4 laboratory abnormalities were reported.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Metformin Premedication for Hyperglycemia Adverse Reactions</u></p><p><u>&nbsp;</u></p><p>The safety of PIQRAY and endocrine therapy with metformin premedication was evaluated in METALLICA (NCT04300790), a single-arm, two-cohort study in 68 patients with HR-positive, HER2-negative advanced breast cancer harboring PIK3CA mutation(s). The majority of patients (93%) received fulvestrant as endocrine therapy during the study.</p><p>&nbsp;</p><p>Cohort A enrolled patients with normal glycemic status (FPG &lt; 100 mg/dl [&lt; 5.6 mmol/L] and HbA1c &lt; 5.7%) and Cohort B enrolled patients with impaired glycemic status (FPG 100&ndash;140 mg/dL [5.6&ndash;7.8 mmol/L] or HbA1c 5.7%&ndash;6.4%).</p><p>&nbsp;</p><p>Metformin was administered beginning 7 days prior to treatment with PIQRAY. On Day 1 to Day 3, metformin 500 mg twice daily was administered orally and then increased up to 1,000 mg twice daily based on tolerability.</p><p>&nbsp;</p><p>Hyperglycemia adverse reactions occurred in 33% (16/48) and 70% (14/20 patients) in Cohort A and Cohort B, respectively. Grade 3-4 hyperglycemia occurred in 2.1% (1/48) of patients in Cohort A and 15% (3/20) of patients in Cohort B. The incidence of nausea, vomiting, and diarrhea adverse reactions, including Grade 3 diarrhea, increases with metformin premedication [see Warnings and Precautions (4.4)].</p><p>Serious adverse reactions occurred in 22% of patients in the METALLICA study and serious adverse reactions &ge; 2% included diarrhea (3%), rash (3%) and vomiting (3%).</p><p>&nbsp;</p><p>The most common Grade 3-4 adverse reactions (&ge; 5%) were rash (16%), diarrhea (13%), and hyperglycemia (6%).&nbsp;</p><p>Permanent discontinuation of PIQRAY due to adverse reactions in the METALLICA study occurred in 19% of patients, and dose modification or interruption of PIQRAY due to adverse reactions occurred in 56% of patients, of which 28% were dose reductions.&nbsp;</p><p>The most common adverse reactions (&ge; 30%) in the METALLICA study were diarrhea (68%), nausea (68%), fatigue (46%), hyperglycemia (44%), rash (38%), and vomiting (34%).</p><p><strong>Postmarketing Experience</strong></p><p>The following adverse reactions have been identified during post approval use of PIQRAY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p><em>Eye disorders:</em> Uveitis</p><p><em>Gastrointestinal disorders: </em>Colitis</p><p><em>Metabolism and nutrition disorders: </em>Hyperglycemic hyperosmolar nonketotic syndrome (HHNKS).</p><p><em>Skin and subcutaneous tissue disorders:</em> Angioedema, Drug reaction with eosinophilia and systemic symptoms (DRESS).</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any complaint(s): complaints.ksa@novartis.com</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited experience of overdose with PIQRAY in clinical trials. In the clinical studies, PIQRAY was administered at doses up to 450 mg once daily.</p><p>In cases where accidental overdosage of PIQRAY was reported in the clinical studies, the adverse reactions associated with the overdose were consistent with the known safety profile of PIQRAY and included hyperglycemia, nausea, asthenia, and rash.</p><p>Initiate general symptomatic and supportive measures in all cases of overdosage where necessary. There is no known antidote for PIQRAY.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>5.1 Pharmacodynamic properties</strong></p><p><strong>&nbsp;</strong></p><p>PIQRAY (alpelisib) is a kinase inhibitor. The chemical name of alpelisib is (2<em>S</em>)-<em>N</em><sup>1</sup>-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide. Alpelisib is a white to almost white powder. The molecular formula for alpelisib is C<sub>19</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S and the relative molecular mass is 441.47 g/mol. The chemical structure of alpelisib is shown below:</p><p><strong>&nbsp;</strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
   style='width:134.25pt;height:142.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AHMEDAR2/AppData/Local/Temp/msohtmlclip1/01/clip_image001.wmz"
    o:title=""/>
  </v:shape><![endif]--><img width="179" height="190" src="file:///C:/Users/AHMEDAR2/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></p><p>&nbsp;</p><p>PIQRAY film-coated tablets are supplied for oral administration with three strengths that contain 50 mg, 150 g and 200 mg of alpelisib. The tablets also contain hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, and sodium starch glycolate. The film-coating contains hypromellose, iron oxide black, iron oxide red, macrogol/polyethylene glycol (PEG) 4000, talc, and titanium dioxide.</p><p><u>Mechanism of action</u></p><p>Alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K&alpha;. Gain-of-function mutations in the gene encoding the catalytic &alpha;-subunit of PI3K (PIK3CA) lead to activation of PI3K&alpha; and Akt-signaling, cellular transformation and the generation of tumors in in vitro and in vivo<em> </em>models.</p><p>In breast cancer cell lines, alpelisib inhibited the phosphorylation of PI3K downstream targets, including Akt and showed activity in cell lines harboring a PIK3CA mutation. In vivo, alpelisib inhibited the PI3K/Akt signaling pathway and reduced tumor growth in xenograft models, including models of breast cancer.</p><p>PI3K inhibition by alpelisib treatment has been shown to induce an increase in estrogen receptor (ER) transcription in breast cancer cells. The combination of alpelisib and fulvestrant demonstrated increased anti-tumor activity compared to either treatment alone in xenograft models derived from ER-positive, PIK3CA mutated breast cancer cell lines.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p><em>Cardiac Electrophysiology</em></p><p>Serial ECGs were collected following a single dose and at steady-state to evaluate the effect of alpelisib on the QTcF interval in patients with advanced cancer. An analysis of clinical ECG data demonstrates the absence of a large effect (i.e., &gt; 20 ms) on QTcF prolongation at the recommended 300 mg dose with or without fulvestrant.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>SOLAR-1 (NCT02437318) was a randomized, double-blind, placebo-controlled trial of PIQRAY plus fulvestrant versus placebo plus fulvestrant in 572 patients with HR-positive, HER2-negative, advanced or metastatic breast cancer whose disease had progressed or recurred on or after an aromatase inhibitor-based treatment (with or without CDK4/6 combination). Patients were excluded if they had inflammatory breast cancer, diabetes mellitus Type 1 or uncontrolled Type 2, or pneumonitis. Randomization was stratified by presence of lung and/or liver metastasis and previous treatment with CDK4/6 inhibitor(s). Overall, 60% of enrolled patients had tumors with one or more PIK3CA mutations in tissue, 50% had liver/lung metastases, and 6% had previously been treated with a CDK4/6 inhibitor.</p><p>There were 341 patients enrolled by tumor tissue in the cohort with a PIK3CA mutation and 231 enrolled in the cohort without a PIK3CA mutation. Of the 341 patients in the cohort with a PIK3CA mutation, 336 (99%) patients had one or more PIK3CA mutations confirmed in tumor tissue using the FDA-approved <em>therascreen</em><sup>&reg;</sup> PIK3CA RGQ PCR Kit. Out of the 336 patients with PIK3CA mutations confirmed in tumor tissue, 19 patients had no plasma specimen available for testing with the FDA-approved <em>therascreen</em><em><sup>&reg;</sup></em> PIK3CA RGQ PCR Kit. Of the remaining 317 patients with PIK3CA mutations confirmed in tumor tissue, 177 patients (56%) had PIK3CA mutations identified in plasma specimen, and 140 patients (44%) did not have PIK3CA mutations identified in plasma specimen.</p><p>Patients received either PIQRAY (300 mg) or placebo orally once daily on a continuous basis, plus fulvestrant (500 mg) administered intramuscularly on Cycle 1, Days 1 and 15, and then on Day 1 of every 28-day cycle. Patients received treatment until radiographic disease progression or unacceptable toxicity. Tumor assessments were performed every 8 weeks for the first 18 months and every 12 weeks thereafter.</p><p>The median age of patients was 63 years (range 25 to 92). Most patients were women (99.8%) and most patients were White (66%), followed by Asian (22%), Other/Unknown (10%), Black or African American (1.4%), and American Indian or Alaskan Native (0.9%). Baseline ECOG performance status was 0 (68%) or 1 (32%).</p><p>Patient demographics for those with PIK3CA-mutated tumors were generally representative of the broader study population. The median duration of exposure to PIQRAY plus fulvestrant was 8.2 months with 59% of patients exposed for &gt; 6 months.</p>&nbsp;<p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>The majority of patients (98%) received prior hormonal therapy as the last treatment (48% metastatic setting, 52% adjuvant setting). Primary endocrine resistance, defined as relapsed within 24 months on adjuvant endocrine therapy or progression within 6 months on endocrine therapy for advanced disease, was observed in 13% of patients and secondary endocrine resistance, defined as relapsed after 24 months on adjuvant endocrine therapy, relapsed within 12 months of the end of adjuvant endocrine therapy, or progression after 6 months on endocrine therapy for advanced disease, was observed in 72% of patients.</p><p>The major efficacy outcome was investigator-assessed progression-free survival (PFS) in the cohort with a PIK3CA mutation per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additional efficacy outcome measures were overall response rate (ORR) and overall survival (OS) in the cohort with a PIK3CA mutation.</p><p>The results from the investigator-assessed PFS and ORR for the cohort with a PIK3CA mutation in tumor tissue are presented in Table 8 and Figure 1. Investigator-assessed PFS results for the cohort with a PIK3CA mutation were supported by consistent results from a blinded independent review committee (BIRC) assessment. Similar results were seen in patients with tissue or plasma PIK3CA mutations. At the pre-specified final OS analysis, there was no significant difference in OS between the PIQRAY plus fulvestrant arm, and the placebo plus fulvestrant arm (hazard ratio [HR] = 0.86, 95% CI: 0.64, 1.15).</p><p>No benefit was observed in patients whose tumors did not have a PIK3CA tissue mutation (PFS:HR = 0.85; 95% CI: 0.58, 1.25; OS: HR = 0.92, 95% CI: 0.65, 1.29).</p><p><strong>Table 8: Efficacy Results in SOLAR-1 (Per Investigator Assessment of Patients with a PIK3CA Tumor Mutation)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:721px"><thead><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>PIQRAY plus fulvestrant</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Placebo plus fulvestrant</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Progression-free survival</strong></p></td><td style="vertical-align:top"><p><strong>N&nbsp;=&nbsp;169</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>N&nbsp;=&nbsp;172</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Number of PFS events &ndash; n (%)</p></td><td style="vertical-align:top"><p>103 (61)</p></td><td colspan="3" style="vertical-align:top"><p>129 (75)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Median PFS months (95% CI)</p></td><td style="vertical-align:top"><p>11.0 (7.5, 14.5)</p></td><td colspan="3" style="vertical-align:top"><p>5.7 (3.7, 7.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio (95% CI)<sup> </sup></p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.65 (0.50, 0.85)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-value<sup>1</sup></p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0013</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Response Rate</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N = 126</strong></p></td><td style="vertical-align:top"><p><strong>N = 136</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ORR<sup>2</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>35.7 (27.4, 44.7)</p></td><td colspan="2" style="vertical-align:top"><p>16.2 (10.4, 23.5)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>Abbreviation: CI, confidence interval.</sup></p><p><sup>1</sup> p-value obtained from the two sided stratified log-rank test stratified by prior CDK4/6 inhibitor usage and presence of</p><p>lung/liver metastases. P-value was compared to prespecified Haybittle-Peto efficacy boundary (two-sided p&nbsp;&le;&nbsp;0.0398).</p><p><sup>2</sup> ORR = percentage of patients with confirmed Complete Response or Partial Response with measurable disease at baseline</p></td></tr></thead><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table></td></tr></tbody></table><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><o:wrapblock><v:shape
    id="Picture_x0020_3" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
    left:0;text-align:left;margin-left:0;margin-top:38.6pt;width:426.85pt;
    height:396pt;z-index:251661312;visibility:visible;mso-wrap-style:square;
    mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
    mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
    mso-wrap-distance-bottom:0;mso-position-horizontal:center;
    mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
    mso-position-vertical-relative:text;mso-width-percent:0;
    mso-height-percent:0;mso-width-relative:page;mso-height-relative:page'>
    <v:imagedata src="file:///C:/Users/AHMEDAR2/AppData/Local/Temp/msohtmlclip1/01/clip_image003.emz"
     o:title=""/>
    <w:wrap type="topAndBottom" anchorx="margin"/>
   </v:shape><![endif]--><img width="569" height="528" src="file:///C:/Users/AHMEDAR2/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" /><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Figure 1: Progression Free Survival in SOLAR-1 </strong><strong>(Per Investigator Assessment of Patients with a PIK3CA Tumor Mutation) </strong></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>The pharmacokinetics of alpelisib has been studied in healthy subjects and adult patients with solid tumors. Steady-state alpelisib maximum plasma concentration (C<sub>max</sub>) and AUC increased proportionally over the dose range of 30 mg to 450 mg (0.1 to 1.5 times the approved recommended dosage) under fed conditions. The mean accumulation of alpelisib is 1.3 to 1.5 and steady-state plasma concentrations are reached within 3 days following daily dosage. In adult patients who received PIQRAY 300 mg once daily in the SOLAR-1 trial, population approach derived mean steady-state alpelisib [coefficient of variation (CV%)] for C<sub>max</sub> was 2480 (23%) ng/mL and AUC<sub>0-24hr </sub>was 33224 (21%) ng*h/mL.</p><p><u>Absorption</u></p><p>The median time to reach peak plasma concentration (T<sub>max</sub>) ranged between 2.0 to 4.0 hours.</p><p><em>Effect of food </em></p><p>A high-fat high-calorie meal (985 calories with 58.1 g of fat) increased alpelisib AUC<sub> </sub>by 73% and C<sub>max</sub> by 84%, and a low-fat low-calorie meal (334 calories with 8.7 g of fat) increased alpelisib AUC by 77% and C<sub>max</sub> by 145% following a single dose of PIQRAY. No clinically significant differences in alpelisib AUC were observed between low-fat low-calorie and high-fat high-calorie meals.</p><p><u>Distribution</u></p><p>The mean (% CV) apparent volume of distribution of alpelisib at steady-state is predicted to be 114 L (46%). Protein binding of alpelisib is 89% and is independent of concentration.</p><p><u>Elimination</u></p><p>The half-life of alpelisib is predicted to be 8 to 9 hours. The mean (% CV) clearance of alpelisib is predicted to be 9.2 L/hr (21%) under fed conditions.</p><p><em>Metabolism</em></p><p>Alpelisib<em> </em>is primarily metabolized<em> </em>by chemical and enzymatic hydrolysis to form its metabolite BZG791 and followed by CYP3A4, mediated hydroxylation.</p><p><em>Excretion</em></p><p>Following a single oral dose of 400 mg radiolabeled alpelisib under fasted condition, 81% of the administered dose was recovered in feces (36% unchanged, 32% BZG791) and 14% (2% unchanged, 7.1% BZG791) in urine. CYP3A4-mediated metabolites (12%) and glucuronides amounted to approximately 15% of the dose.</p><p><u>Specific Populations </u></p><p>No clinically significant differences in the pharmacokinetics of alpelisib were predicted based on age (21 to 87 years), sex, race/ethnicity (Japanese or Caucasian), body weight (37 to 181 kg), mild to moderate renal impairment (CLcr 30 to &lt; 90 mL/min based on the Cockcroft-Gault formula), or mild to severe hepatic impairment (Child-Pugh Class A, B, and C). The effect of severe renal impairment (CLcr &lt; 30 mL/min) on the pharmacokinetics of alpelisib is unknown.</p><p><u>Drug Interaction Studies</u></p><p><em>Clinical Studies </em></p><p><em>Acid Reducing Agents</em>: PIQRAY can be coadministered with acid reducing agents, since PIQRAY should be taken with food. Food exhibited a more pronounced effect on the solubility of alpelisib than the effect of gastric pH value.</p><p>Coadministration of the H<sub>2</sub> receptor antagonist ranitidine in combination with a single 300 mg oral dose of alpelisib decreased the absorption and overall exposure of alpelisib. In the presence of a low-fat low-calorie meal, AUC was decreased on average by 21% and C<sub>max </sub>by 36% with ranitidine. Under the fasted state, AUC was decreased on average by 30% and C<sub>max </sub>by 51% with ranitidine.</p><p><em>CYP3A4, CYP2C8, CYP2C9, CYP2C19 and CYP2B6 Substrates: Coadministration of repeated doses of alpelisib 300 mg with a single-dose of sensitive substrates of CYP3A4 (midazolam), CYP2C8 (repaglinide), CYP2C9 (warfarin), CYP2C19 (omeprazole) and CYP2B6 (bupropion), administered as a cocktail did not show clinically significant pharmacokinetic interactions</em><em>.</em> No clinically significant differences in pharmacokinetics of everolimus (a substrate of CYP3A4 and P-gp) were observed when coadministered with alpelisib.</p><p><em>Effect of CYP3A4 Inducers on Alpelisib:</em> Coadministration of repeat doses of rifampin (a strong CYP3A4 inducer) with a single 300 mg dose of alpelisib decreased alpelisib C<sub>max</sub> by 38% and AUC by 57%, respectively. Coadministration of rifampin with repeat doses of 300 mg alpelisib decreased alpelisib C<sub>max</sub> by 59% and AUC by 74%, respectively.</p><p><em>Model-Informed Approaches</em></p><p>Coadministration of repeat doses of ketoconazole (a strong CYP3A4 inhibitor) with a single 300 mg dose of alpelisib is expected to increase alpelisib AUC by 37% or less.</p><p>Coadministration of repeat doses of efavirenz (a moderate CYP3A4 inducer) with a single 300 mg dose of alpelisib is expected to decrease alpelisib AUC by 30% or less.</p><p><em>In Vitro Studies</em></p><p><em>Effect of Transporter on Alpelisib:</em> Alpelisib is a substrate of BCRP.</p><p><em>Effect of Alpelisib on Transporters:</em> Alpelisib is an inhibitor of P-gp. Alpelisib has a low potential to inhibit BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OCT1, OAT1, OAT3, OCT2, MATE1, and MATE2K at clinically relevant concentrations.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></p><p>Carcinogenicity studies have not been conducted with alpelisib.</p><p>Alpelisib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay, or aneugenic or clastogenic in human cell micronucleus and chromosome aberration tests in vitro. Alpelisib was not genotoxic in an in vivo rat micronucleus test.</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>In a fertility and early embryonic development study in rats, female animals were administered alpelisib at doses of 3, 10, and 20 mg/kg/day orally. Animals were dosed for 4 weeks prior to pairing, during the mating period, and up to Gestation Day 6. At a dose of 20&nbsp;mg/kg/day (approximately 1.7 times the exposure in humans at the recommended dose of 300 mg based on AUC), alpelisib increased pre- and post-implantation losses, leading to reduced numbers of implantation sites and live embryos. In a repeated-dose toxicity study in rats, adverse effects in female reproductive organs included vaginal atrophy and estrous cycle variations in rats at doses &ge; 6 mg/kg/day (approximately 0.6 times the exposure in humans at the recommended dose of 300 mg/day based on AUC).</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>In a male fertility study, alpelisib administered orally at doses of 3, 10, and 20 mg/kg/day for up to 99 days (10- weeks prior to pairing, during mating period and continuing during post-pairing) to male rats, resulted in reduced weights of seminal vesicles and prostate, which correlated with atrophy and/or reduced secretion in prostate and seminal vesicles at &ge; 10&nbsp;mg/kg/day (approximately 0.8 times the exposure in humans at the recommended dose of 300 mg based on AUC). No adverse effects on male fertility parameters were observed at doses up to 20 mg/kg/day.</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Microcrystalline cellulose</p><p>Mannitol</p><p>Sodium starch glycolate</p><p>Hypromellose</p><p>Magnesium stearate</p><p><u>Film coating</u></p><p>Hypromellose</p><p>Iron oxide</p><p>Titanium dioxide</p><p>Polyethylene glycol</p><p>Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PCTFE (polyvinylchloride/polychlorotrifluoroethylene) or PA/alu/PVC (polyamide/aluminium/polyvinylchloride) blisters containing 14&nbsp;film‑coated tablets.</p><p>&nbsp;</p><p><u>Piqray 50&nbsp;mg and 200&nbsp;mg film‑coated tablets</u></p><p>&nbsp;</p><p>Unit packs containing 28&nbsp;film‑coated tablets (14 of 50&nbsp;mg and 14 of 200&nbsp;mg) or 56&nbsp;film‑coated tablets (28 of 50&nbsp;mg and 28 of 200&nbsp;mg).</p><p>Multipacks containing 168&nbsp;film‑coated tablets (3x 56, each comprising 28&nbsp;tablets of 50&nbsp;mg and 28&nbsp;tablets of 200&nbsp;mg).</p><p>&nbsp;</p><p><u>Piqray 150&nbsp;mg film‑coated tablets</u></p><p>&nbsp;</p><p>Unit packs containing 28 or 56&nbsp;film‑coated tablets.</p><p>Multipacks containing 168 (3x 56) film‑coated tablets.</p><p>&nbsp;</p><p><u>Piqray 200&nbsp;mg film‑coated tablets</u></p><p>&nbsp;</p><p>Unit packs containing 14 or 28&nbsp;film‑coated tablets.</p><p>Multipacks containing 84 (3x 28) film‑coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by USFDA in 01/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>